Assay Engineers
THe Next-Generation Cancer-CRO
Advancing precision oncology through patient relevant models and multi-dimensional functional profiling
Driving Translational Success in Cancer Research
Assay Engineers is a specialized Cancer-CRO offering patient-derived tumor models and cutting-edge functional assays to deliver actionable insights into tumor biology.
Our integrated platforms – AutoTIL™ Microtumors, Hyperplex™ Proteomics and QSM™ Metabolic Phenotyping – provide high-resolution, predictive data that translate preclinical findings into actionalbe insights for clinical development.
Services
Drug development support
Reduce Translational Risk with AutoTIL™ Microtumors
Advance immune-oncology research with Assay Engineers' AutoTIL™ Microtumors—immune-competent, patient-derived tumor models containing autologous tumor-infiltrating lyphocytes (TILs). AutoTIL™ Microtumors preserve native tumor-immune interactions, providing clinically relevant insights into immune response and resistance mechanisms.
Accelerate Cancer Drug Discovery with Signaling Pathway Analysis
Translate biomarker concentrations into functional insights across all major signaling pathways. Hyperplex™ enables detection of dysregulated pathways and clinically relevant markers to guide early drug development. This approach provides predictive, data-driven results to improve translational outcomes.
Stratify Responders and Non-Responders with Confidence
Identify responders and non-responders early to refine therapeutic strategies and improve clinical relevance. Functional 3D tumor-immune co-culture assays provide real-time measurements of TIL infiltration, activation, and cytotoxicity. These analyses deliver actionable, mechanistic data that guide candidate prioritization and support mechanism-driven immuno-oncology development.
Enable Breakthroughs with Mode of Action Identification
Reveal novel biomarkers, resistance pathways, regulatory mechanisms and metabolic vulnerabilities with comprehensive mode of action analysis. Assay Engineers uncovers how therapies exert their effects and why patients respond differently. These findings inform smarter therapeutic strategies and accelerate oncology drug development.
Empower Precision Medicine with Metabolic Profiling
Quantify tumor energy metabolism across key pathways—including ATP production, glycolysis, OXPHOS, and mitochondrial respiration—using QSM™. Gain systems-level insights into metabolic dependencies and pharmacodynamic responses, even FFPE samples. These data support candidate prioritization, mechanism-driven strategy design, and translational decision-making in oncology drug development.
At Assay Engineers, we cultivate scientific excellence and collaboration, embracing diverse perspectives while staying at the forefront of proteomic advancements.
Our Core Technologies
for breakthrough bioanalytical data in Cancer Research
As platform-independent bioanalytical CRO, we support precision medicine through translational sciences ranging from biomarker discovery through validation and patient cohort stratification. Based on a concise description of the biomarker’s specified use, we help selecting the appropriate bioanalysis platform using a fit-for-purpose approach.
Hyperplex™ Proteomics -
High-dimensional mapping of cancer signaling networks
• Feature: A 1,500-plex “Western Blot” platform for simultaneous quantification of proteins and phosphoproteins.
• Advantage: Reveals cancer signaling pathways, therapy response signatures, and resistance mechanisms at unprecedented resolution.
• Benefit: Accelerates the development of targeted therapies and supports data-driven decision-making in drug discovery
AutoTIL™ Microtumors - Patient derived microtumors with autologous TILs for accurate immunotherapy
• Feature: Integrates autologous immune cells with patient-derived microtumors, preserving the native tumor microenvironment.
• Advantage: Reveals cancer signaling pathways, therapy response signatures, and resistance mechanisms at unprecedented resolution.
• Benefit: Generates clinically meaningful insights, improving translational predictivity and reducing late-stage clinical failures.
QSM™ Metabolomics - Quantitative bioenergetics for therapeutic optimization
• Feature: Comprehensive metabolic phenotyping of ATP generation, mitochondrial respiration, and substrate utilization.
• Advantage: The first platform to provide quantitative pharmacokinetic assessment of critical bioenergetic biomarkers at the cellular level.
• Benefit: Enables precise bioenergetic pharmacokinetic profiling of drug candidates, accelerating therapeutic optimization and decision-making.
Why Leading Oncology Researchers Choose Us
- Oncology-Specialized Expertise
A dedicated Cancer-CRO with deep expertise in functional tumor biology - Actionable, High-Resolution Insights
Advanced profiling platforms provide data that inform smarter therapeutic decisions - Patient-Relevant Models
AutoTIL™ Microtumors preserve native complexity for clinically predictive outcomes - Collaborative Research Approach
Partnering with biotech, pharma, and academia to deliver customized research solutions
- Oncology-Specialized Expertise
A dedicated Cancer-CRO with deep expertise in functional tumor biology - Actionable, High-Resolution Insights
Advanced profiling platforms provide data that inform smarter therapeutic decisions - Patient-Relevant Models
AutoTIL™ Microtumors preserve native complexity for clinically predictive outcomes - Collaborative Research Approach
Partnering with biotech, pharma, and academia to deliver customized research solutions
Be a part of us…
Summarize your expertise and motivation in a single pdf file and send it to us, if you wish to join assay engineers.